Skip to main content
Alzheimer's & Dementia logoLink to Alzheimer's & Dementia
. 2025 Dec 23;21(Suppl 6):e104896. doi: 10.1002/alz70860_104896

A Multidomain Lifestyle Intervention in Dutch Older Adults to Prevent Cognitive Decline (FINGER‐NL): from RCT to follow‐up study

Marissa D Zwan 1,2, Kay Deckers 3, Lisa Waterink 1,2, Lion M Soons 3, Sonja Beers 4, Sofie van Houdt 5,6, Berrit Stienstra 7, Judith Z Kwant 8, Sophie CPM Wimmers 3, Rachel AM Heutz 9, Jurgen AHR Claassen 10,11,12, Joukje M Oosterman 11, Rianne AA de Heus 13,14, Ondine van de Rest 4, Yannick Vermeiren 4, Richard C Oude Voshaar 15, Nynke Smidt 7, Laus M Broersen 16, Sietske AM Sikkes 1,2,17, Esther Aarts 11, Wiesje M van der Flier 2,18,19, Sebastian Köhler 3,✉, MOCIA consortium 1, FINGER‐NL consortium 1
PMCID: PMC12726521

Abstract

Background

FINGER‐NL aims to investigate the effectiveness of a 2‐year multidomain lifestyle intervention to maintain optimal cognitive functioning in Dutch at‐risk older adults. Here we provide an update on the progress and follow‐up of this study.

Methods

Embedded in the World‐Wide FINGERS initiative and as part of the MOCIA research programme, FINGER‐NL is a 24‐month Dutch multi‐center, randomized, controlled, multidomain lifestyle intervention trial among adults at risk for cognitive decline. Inclusion criteria are 60‐80 years of age and presence of both modifiable (based on LIfestyle for BRAin health (LIBRA) score) and non‐modifiable (positive family history of dementia or self‐reported subjective cognitive decline) risk factors. Participants were randomized to either a high‐intensity (personalized, supervised hybrid program with group meetings and individual sessions) or a low‐intensity (digital information) lifestyle intervention group. Efforts are ongoing to expand and enrich FINGER‐NL

Results

Between February 2022 and May 2023, we screened 2057 individuals and randomly assigned 1210 eligible individuals to the high‐intensity (n = 605) or low‐intensity group (n = 605). One‐year follow‐up assessments have been completed and carried out in 544 (90%) participants in the high‐intensity group and 505 (83%) in the low‐intensity group. Two‐year follow‐up assessments are ongoing, with currently 369 completed assessments in the high‐intensity group (and n = 52 (12%) participants lost to follow‐up) and 358 completed assessments in the low‐intensity group (and n = 92 (20%) participants lost to follow‐up). Using stored biomaterials, blood‐based biomarker analyses and measurement of genetic variations are planned in 2025. Funding has been secured for additional follow‐up measurements at three and four years after baseline to determine sustained effects on cognitive performance and lifestyle after completion of the intervention. Currently, 456 (74%) participants who completed the intervention consented to participate in the extension study.

Conclusion

FINGER‐NL is progressing well. Point of attention is participant adherence, especially in the low‐intensity group. There is high interest among participants to continue their participation with additional follow‐up measurements after completion of the intervention. Extension of the project and (inter) national (joint) initiatives expand and enrich FINGER‐NL, which enables and stimulates data sharing and joint analyses across WW‐FINGER studies.


Articles from Alzheimer's & Dementia are provided here courtesy of Wiley

RESOURCES